Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Mike Andriole, the company's CEO, will deliver a corporate presentation on September 9, 2024, at 7:00 a.m. ET.

The presentation will be made available as an audio webcast on the Investor Relations section of Chimerix's website at ir.chimerix.com. Interested parties can access the webcast, which will remain archived on the site for approximately 90 days. This event provides an opportunity for investors and analysts to gain insights into Chimerix's latest developments and future strategies.

News Market Reaction – CMRX

-7.01%

-7.01% Session move

In the trading session that priced this news, CMRX declined 7.01%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.   The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

CONTACT:

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

When is Chimerix (CMRX) presenting at the H.C. Wainwright Global Investment Conference?

Chimerix (CMRX) will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET.

Who will be presenting for Chimerix (CMRX) at the investment conference?

Mike Andriole, the Chief Executive Officer of Chimerix (CMRX), will deliver the corporate presentation at the conference.

How can investors access Chimerix's (CMRX) presentation at the H.C. Wainwright conference?

Investors can access an audio webcast of Chimerix's (CMRX) presentation on the Investor Relations section of the company's website at ir.chimerix.com.

How long will Chimerix's (CMRX) presentation be available on their website?

The audio webcast of Chimerix's (CMRX) presentation will be archived on their website for approximately 90 days.